acetylcarnitine has been researched along with Mitochondrial Diseases in 6 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Mitochondrial Diseases: Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 7.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 3.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "Rhabdomyolysis is common in very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) and other metabolic myopathies, but its pathogenic basis is poorly understood." | 1.43 | Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency. ( de Sain-van der Velden, M; Diekman, EF; Houten, SM; Jeneson, JA; Nievelstein, RA; Schmitz, JP; Takken, T; Van der Pol, WL; van Riel, NA; Visser, G; Wardrop, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, X | 1 |
| Qi, Y | 1 |
| Zhang, X | 1 |
| Gu, X | 1 |
| Cai, H | 1 |
| Yang, J | 1 |
| Zhang, Y | 1 |
| Mehrotra, A | 1 |
| Kanwal, A | 1 |
| Banerjee, SK | 1 |
| Sandhir, R | 1 |
| Diekman, EF | 1 |
| Visser, G | 1 |
| Schmitz, JP | 1 |
| Nievelstein, RA | 1 |
| de Sain-van der Velden, M | 1 |
| Wardrop, M | 1 |
| Van der Pol, WL | 1 |
| Houten, SM | 1 |
| van Riel, NA | 1 |
| Takken, T | 1 |
| Jeneson, JA | 1 |
| Alves, E | 1 |
| Binienda, Z | 1 |
| Carvalho, F | 1 |
| Alves, CJ | 1 |
| Fernandes, E | 1 |
| de Lourdes Bastos, M | 1 |
| Tavares, MA | 1 |
| Summavielle, T | 1 |
| Shen, W | 1 |
| Liu, K | 1 |
| Tian, C | 1 |
| Yang, L | 1 |
| Li, X | 1 |
| Ren, J | 1 |
| Packer, L | 1 |
| Head, E | 1 |
| Sharman, E | 1 |
| Liu, J | 1 |
| Kottlors, M | 1 |
| Jaksch, M | 1 |
| Ketelsen, UP | 1 |
| Weiner, S | 1 |
| Glocker, FX | 1 |
| Lücking, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acute Nutritional Ketosis and Exercise in Glycogen Storage Disease Type IIIa[NCT03011203] | 6 participants (Actual) | Interventional | 2017-02-10 | Completed | |||
| Acute Nutritional Ketosis in VLCAD Deficiency: Testing the Metabolic Base for Therapeutic Use[NCT03531554] | 5 participants (Actual) | Interventional | 2016-04-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for acetylcarnitine and Mitochondrial Diseases
| Article | Year |
|---|---|
ROS act as an upstream signal to mediate cadmium-induced mitophagy in mouse brain.
Topics: Acetylcarnitine; Acetylcysteine; Analysis of Variance; Animals; Brain; Cadmium; Collagenases; Dose-R | 2015 |
Mitochondrial modulators in experimental Huntington's disease: reversal of mitochondrial dysfunctions and cognitive deficits.
Topics: Acetylcarnitine; Animals; Cognition Disorders; Drug Therapy, Combination; Female; Huntington Disease | 2015 |
Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
Topics: Acetylcarnitine; Acyl-CoA Dehydrogenase, Long-Chain; Adenosine Triphosphate; Adolescent; Adult; Case | 2016 |
Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
Topics: Acetylcarnitine; Acyl-CoA Dehydrogenase, Long-Chain; Adenosine Triphosphate; Adolescent; Adult; Case | 2016 |
Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
Topics: Acetylcarnitine; Acyl-CoA Dehydrogenase, Long-Chain; Adenosine Triphosphate; Adolescent; Adult; Case | 2016 |
Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
Topics: Acetylcarnitine; Acyl-CoA Dehydrogenase, Long-Chain; Adenosine Triphosphate; Adolescent; Adult; Case | 2016 |
Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain.
Topics: Acetylcarnitine; Animals; Body Weight; Brain; Cyclooxygenase 1; DNA, Mitochondrial; Fever; Hallucino | 2009 |
Protective effects of R-alpha-lipoic acid and acetyl-L-carnitine in MIN6 and isolated rat islet cells chronically exposed to oleic acid.
Topics: Acetylcarnitine; Animals; Cell Line, Tumor; Insulinoma; Islets of Langerhans; Mitochondrial Diseases | 2008 |
Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency.
Topics: Acetylcarnitine; Acute Disease; Antimanic Agents; Bipolar Disorder; Carnitine O-Palmitoyltransferase | 2001 |